SAM
PGNX

Shell Asset Management’s Progenics Pharmaceuticals Inc PGNX Stock Holding History

Shell Asset Management’s Portfolio PGNX Stock Details PGNX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q3 		– Sell
-47,978
Closed -$326K – 1126
2017
Q2 		$326K Hold
47,978
– – 0.01% 993
2017
Q1 		$453K Buy
+47,978
New +$479K 0.01% 927

Other funds holding PGNX

Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
EAM
Eagle Asset Management St Petersburg, Florida $19.6B AUM 41.58% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
PA
Pinnacle Associates New York $7.78B AUM 45.07% 1-Year Est. Return
AAP
Ardsley Advisory Partners Stamford, Connecticut $960M AUM 207.76% 1-Year Est. Return
RHJA
Rice Hall James & Associates San Diego, California $1.8B AUM 36.16% 1-Year Est. Return

Shell Asset Management's PGNX Position: Q3 2017 in Review

Shell Asset Management sold out of Progenics Pharmaceuticals Inc (PGNX) in Q3 2017, closing a stake of 47,978 shares — an estimated $326K sold.

Shell Asset Management first reported a position in PGNX in Q1 2017 and held it in 2 quarters. The position peaked at $453K in Q1 2017. 142 funds tracked by Wall St. Rank hold PGNX as of Q3 2017.

  • Shell Asset Management reported no remaining Progenics Pharmaceuticals Inc position as of Q3 2017 after selling out during the quarter.
  • Shell Asset Management sold 47,978 Progenics Pharmaceuticals Inc shares in Q3 2017, an estimated $326K.
  • Shell Asset Management first reported a position in Progenics Pharmaceuticals Inc in Q1 2017 and held it in 2 quarters.
  • Shell Asset Management's Progenics Pharmaceuticals Inc position peaked at $453K in Q1 2017.
  • 142 funds tracked by Wall St. Rank held Progenics Pharmaceuticals Inc as of Q3 2017.

Based on Shell Asset Management's 13F filing for Q3 2017, filed 18 Oct 2017.